Yatharth Hospit.

  • Market Cap: Small Cap
  • Industry: Hospital
  • ISIN: INE0JO301016
  • NSEID: YATHARTH
  • BSEID: 543950
INR
857.00
10.65 (1.26%)
BSENSE

Aug 14, 04:01 PM

BSE+NSE Vol: 3.14 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

3.14 lacs (-54.30%) Volume

Shareholding (Jun 2026)

FII

5.62%

Held by 58 FIIs

DII

10.84%

Held by 12 DIIs

Promoter

55.80%

Why is Yatharth Hospital & Trauma Care Services Ltd falling/rising?

15-Aug-2026

As of 14-Aug, Yatharth Hospital & Trauma Care Services Ltd's stock price has risen to Rs 857.00, reflecting strong financial performance with a 25.78% growth in profit after tax and record net sales. Despite a recent decline in investor participation, the company's net-debt-free status and significant year-to-date increase of 25.74% indicate strong investor confidence.

As of 14-Aug, Yatharth Hospital & Trauma Care Services Ltd is experiencing a rise in its stock price, currently at Rs 857.00, reflecting an increase of Rs 10.65 or 1.26%. This upward movement can be attributed to several positive factors. The company has demonstrated strong financial performance, having declared positive results for the last 12 consecutive quarters, with a notable growth in profit after tax (PAT) of 25.78% and record net sales of Rs 392.65 crore in the most recent quarter. Additionally, the stock has outperformed the market significantly over the past year, generating a return of 20.21% compared to the BSE500's return of only 3.82%.<BR><BR>Despite a slight underperformance today against its sector, which gained 2.06%, the stock's overall year-to-date performance shows a remarkable increase of 25.74%, indicating strong investor confidence. Furthermore, the company is net-debt free, which enhances its financial stability and attractiveness to investors. However, it is worth noting that there has been a decline in investor participation, as evidenced by a 13.1% drop in delivery volume compared to the 5-day average, which could suggest some caution among investors. Nonetheless, the overall positive financial indicators and market-beating performance contribute to the stock's rising price.

View full answer

Who are in the management team of Yatharth Hospit.?

14-Aug-2026

The management team of Yatharth Hospital includes Ajay Kumar Tyagi (Chairman & Wholetime Director), Kapil Kumar (Managing Director), Yatharth Tyagi (Whole-time Director), and independent directors Mukesh Sharma, Sanjeev Upadhyaya, and Promila Bhardwaj, along with Ritesh Mishra (Company Secretary & Compliance Officer).

The management team of Yatharth Hospital includes the following members:<BR><BR>1. **Ajay Kumar Tyagi** - Chairman & Wholetime Director<BR>2. **Kapil Kumar** - Managing Director<BR>3. **Yatharth Tyagi** - Whole-time Director<BR>4. **Mukesh Sharma** - Independent Director<BR>5. **Sanjeev Upadhyaya** - Independent Director<BR>6. **Promila Bhardwaj** - Independent Director<BR>7. **Ritesh Mishra** - Company Secretary & Compliance Officer<BR><BR>If you have any more questions about the company or its operations, feel free to ask!

View full answer

What does Yatharth Hospit. do?

14-Aug-2026

Yatharth Hospital & Trauma Care Services Ltd is a small-cap company in the hospital industry, incorporated in 2008 and converted to a public company in 2021. As of June 2026, it reported net sales of 393 Cr and a net profit of 47 Cr, with a market cap of INR 8,176 Cr.

Overview: <BR>Yatharth Hospital & Trauma Care Services Ltd operates in the hospital industry and is categorized as a small-cap company.<BR><BR>History: <BR>The company was incorporated in 2008 as a Private Limited Company in Delhi. It converted to a Public Company on November 3, 2021, and changed its name to Yatharth Hospital & Trauma Care Services Limited on November 18, 2021. The most recent quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 393 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 47 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 8,176 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 45.00 <BR>Industry P/E: 67 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.00 <BR>Return on Equity: 9.89% <BR>Price to Book: 4.69<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

View full answer

Who are the peers of the Yatharth Hospit.?

14-Aug-2026

Yatharth Hospital's peers include Dr Agarwal's Health, Rainbow Children's Hospital, Jupiter Life Line, and others. In terms of management risk, growth, and capital structure, Yatharth Hospital has below average ratings, with a 1-year return of 18.54%, higher than Rainbow Children's but lower than Dr Agarwal's Eye at 22.97%.

Peers: The peers of Yatharth Hospit. are Dr Agarwal's Hea, Rainbow Child., Health.Global, Jupiter Life Lin, Jeena Sikho, Kovai Medical, Artemis Medicare, Indrapr.Medical, and Dr Agarwal's Eye.<BR><BR>Quality Snapshot: Excellent management risk is observed at Jupiter Life Lin and Jeena Sikho, while Good management risk is found at Dr Agarwal's Hea, Rainbow Child., Kovai Medical, Artemis Medicare, and Dr Agarwal's Eye. Average management risk is present in Health.Global, Indrapr.Medical, and the rest. Below Average management risk is noted at Yatharth Hospit. In terms of Growth, Excellent growth is seen at Jeena Sikho, Good growth at Dr Agarwal's Hea, Health.Global, Jupiter Life Lin, Artemis Medicare, and Indrapr.Medical, while Average growth is noted at Yatharth Hospit. Below Average growth is found at Rainbow Child. and Kovai Medical. The rest have Below Average growth. For Capital Structure, Excellent capital structure is noted at Jupiter Life Lin, Jeena Sikho, and Indrapr.Medical, while Good capital structure is observed at Dr Agarwal's Hea, Rainbow Child., Kovai Medical, and Artemis Medicare. Below Average capital structure is seen at Health.Global, and Average capital structure is noted at Dr Agarwal's Eye.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Dr Agarwal's Eye at 22.97%, while the lowest is Rainbow Child. at -6.16%. Yatharth Hospit. has a 1-year return of 18.54%, which is significantly higher than Rainbow Child. but lower than Dr Agarwal's Eye. Additionally, Jeena Sikho and Indrapr.Medical have negative six-month returns.

View full answer

How big is Yatharth Hospit.?

14-Aug-2026

As of 14th August, Yatharth Hospital & Trauma Care Services Ltd has a market capitalization of 8,148.21 Cr, with recent net sales of 1,334.10 Cr and a net profit of 181.17 Cr over the last four quarters.

As of 14th August, <BR><BR>Market Cap: Yatharth Hospital & Trauma Care Services Ltd has a market capitalization of 8,148.21 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 1,334.10 Cr, while the sum of Net Profit for the same period is 181.17 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025. Shareholder's Funds are valued at 1,605.46 Cr, and Total Assets amount to 1,713.06 Cr.

View full answer

Should I buy, sell or hold Yatharth Hospital & Trauma Care Services Ltd?

12-Aug-2026

Has Yatharth Hospital & Trauma Care Services Ltd declared dividend?

12-Aug-2026

Yes, Yatharth Hospital & Trauma Care Services Ltd has declared a 5% dividend, with an ex-date of August 14, 2026. Despite this, the dividend yield is 0%, while total returns over various periods show strong price performance.

Yatharth Hospital & Trauma Care Services Ltd has declared a 5% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 5%<BR>- Ex-date: 14 Aug 26<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 3 months, the price return was 6.03%, the dividend return was 0.06%, resulting in a total return of 6.09%.<BR><BR>Over the past 6 months, the price return was 24.89%, the dividend return was 0.07%, leading to a total return of 24.96%.<BR><BR>In the last year, the price return was 22.15%, with a dividend return of 0.07%, culminating in a total return of 22.22%.<BR><BR>For the 2-year period, the price return was 90.13%, the dividend return was 0.10%, which resulted in a total return of 90.23%.<BR><BR>During the 3-year period, the price return was 162.34%, the dividend return was 0.13%, leading to a total return of 162.47%.<BR><BR>In the 4-year period, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>For the 5-year period, the price return was 0% and the dividend return was also 0%, leading to a total return of 0.0%.<BR><BR>Overall, Yatharth Hospital & Trauma Care Services Ltd has declared a dividend, although the dividend yield remains at 0%. The total returns over various periods indicate a strong performance in price returns, particularly over longer durations, despite minimal contributions from dividends.

View full answer

When is the next results date for Yatharth Hospital & Trauma Care Services Ltd?

05-Aug-2026

The next results date for Yatharth Hospital & Trauma Care Services Ltd is August 10, 2026.

The next results date for Yatharth Hospital & Trauma Care Services Ltd is scheduled for August 10, 2026.

View full answer

Are Yatharth Hospital & Trauma Care Services Ltd latest results good or bad?

26-May-2026

Yatharth Hospital & Trauma Care Services Ltd's latest results show strong revenue growth with Q4 FY26 revenues up 47.36% year-on-year, but declining PAT margins to 13.09% raise concerns about sustainability. Overall, the results are mixed, indicating robust growth alongside operational challenges.

Yatharth Hospital & Trauma Care Services Ltd's latest results present a mixed picture. On one hand, the company has shown impressive revenue growth, with Q4 FY26 revenues reaching ₹341.56 crores, marking a 6.58% increase quarter-on-quarter and a remarkable 47.36% increase year-on-year. The net profit for the same quarter was ₹47.52 crores, reflecting a 4.79% rise from the previous quarter and a 22.73% increase year-on-year.<BR><BR>However, there are concerns regarding margin pressures. The PAT margin has declined to 13.09%, down from 16.71% in Q4 FY25, indicating a significant compression of 362 basis points. This decline in profitability metrics raises questions about the sustainability of the company's growth, especially as it continues to expand aggressively.<BR><BR>Overall, while the revenue and profit figures are strong and indicate robust growth, the declining margins suggest that the company is facing operational challenges that investors should monitor closely.

View full answer

How has been the historical performance of Yatharth Hospit.?

15-Nov-2025

Yatharth Hospital has shown significant growth from March 2022 to March 2025, with net sales increasing from 400.94 crore to 880.49 crore, and profit after tax rising from 44.16 crore to 130.55 crore, alongside a substantial improvement in total assets and cash flow. Overall, the hospital has demonstrated robust revenue and profitability growth during this period.

Answer:<BR>The historical performance of Yatharth Hospital shows significant growth in various financial metrics over the past few years.<BR><BR>Breakdown:<BR>Yatharth Hospital's net sales have increased from 400.94 crore in March 2022 to 880.49 crore in March 2025, reflecting a strong upward trend. Total operating income has followed a similar trajectory, rising from 400.94 crore in March 2022 to 880.49 crore in March 2025. The total expenditure, excluding depreciation, also grew from 290.13 crore in March 2022 to 660.30 crore in March 2025, indicating increased operational costs. Operating profit (PBDIT) has seen a notable increase, climbing from 110.81 crore in March 2022 to 236.37 crore in March 2025. Profit before tax rose from 63.11 crore in March 2022 to 171.74 crore in March 2025, while profit after tax increased from 44.16 crore to 130.55 crore in the same period. The company's total assets have surged from 420.57 crore in March 2022 to 1,713.06 crore in March 2025, with total liabilities also rising from 420.57 crore to 1,713.06 crore. Cash flow from operating activities improved significantly, moving from 59 crore in March 2022 to 149 crore in March 2025, contributing to a net cash inflow of 248 crore in March 2025, up from 6 crore in March 2022. Overall, Yatharth Hospital has demonstrated robust growth in revenue, profitability, and asset base over the past few years.

View full answer

Is Yatharth Hospit. technically bullish or bearish?

04-Nov-2025

As of November 3, 2025, Yatharth Hospital's technical trend is mildly bullish, supported by a bullish MACD and moving averages, though caution is advised due to a mildly bearish KST and lack of momentum in the RSI.

As of 3 November 2025, the technical trend for Yatharth Hospital has changed from bullish to mildly bullish. The weekly MACD remains bullish, supported by bullish signals from the Bollinger Bands on both weekly and monthly time frames. The daily moving averages also indicate a bullish stance. However, the KST on a weekly basis is mildly bearish, suggesting some caution. The RSI shows no signal on both weekly and monthly charts, indicating a lack of momentum. Overall, the current technical stance is mildly bullish, driven primarily by the bullish MACD and moving averages, despite some mixed signals from other indicators.

View full answer

Is Yatharth Hospit. overvalued or undervalued?

09-Oct-2025

As of October 8, 2025, Yatharth Hospital is considered very expensive and overvalued, with a PE ratio of 56.35, an EV to EBITDA of 32.50, and a Price to Book Value of 4.99, despite having a lower PE ratio than peers like Max Healthcare and Fortis Healthcare, while significantly outperforming the Sensex with a year-to-date return of 46.93%.

As of 8 October 2025, the valuation grade for Yatharth Hospital has moved from expensive to very expensive, indicating a significant increase in perceived valuation. The company is currently considered overvalued. Key ratios include a PE ratio of 56.35, an EV to EBITDA of 32.50, and a Price to Book Value of 4.99, all of which suggest a high valuation relative to earnings and book value.<BR><BR>In comparison to its peers, Yatharth Hospital's PE ratio is lower than that of Max Healthcare at 92.31 and Fortis Healthcare at 86.26, both of which are also categorized as very expensive. However, it is notably higher than Narayana Hrudaya, which has a PE of 46.14 and is classified as expensive. The recent stock performance has outpaced the Sensex, with a year-to-date return of 46.93% compared to the Sensex's 4.65%, reinforcing the notion that the stock is currently overvalued in the market.

View full answer

Who are the top shareholders of the Yatharth Hospit.?

17-Jul-2025

The top shareholders of Yatharth Hospital include promoter Ajay Kumar Tyagi with 30.59%, mutual funds holding 9.42%, foreign institutional investors at 4.45%, and individual investors with 14.87%. The largest public shareholder is Kotak Mahindra Trustee Co Ltd, representing the Kotak Multicap Fund, with 4.36%.

The top shareholders of Yatharth Hospital include the promoters, who hold the majority of the shares. The promoter with the highest holding is Ajay Kumar Tyagi, with a significant stake of 30.59%. Additionally, mutual funds hold 9.42% of the shares through 8 schemes, while foreign institutional investors (FIIs) account for 4.45% with 30 different FIIs involved. The highest public shareholder is Kotak Mahindra Trustee Co Ltd, representing the Kotak Multicap Fund, which holds 4.36%. Individual investors collectively hold 14.87% of the company's shares.

View full answer
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Poor Management Efficiency with a low ROE of 9.01%

  • The company has been able to generate a Return on Equity (avg) of 9.01% signifying low profitability per unit of shareholders funds
2

The company is Net-Debt Free

 
3

The company has declared Positive results for the last 12 consecutive quarters

4

With ROE of 9.9, it has a Expensive valuation with a 4.6 Price to Book Value

5

Falling Participation by Institutional Investors

stock-summaryMojo Parameters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

stock-summary
Industry

Hospital

stock-summary
Market cap

INR 7,965 Cr (Small Cap)

stock-summary
P/E

46.00

stock-summary
Industry P/E

66

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.00

stock-summary
Return on Equity

9.89%

stock-summary
Price to Book

4.58

Revenue and Profits:
Net Sales:
393 Cr
(Quarterly Results - Jun 2026)
Net Profit:
47 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
2.94%
0.06%
3.0%
6 Months
24.95%
0.07%
25.02%
1 Year
20.21%
0.07%
20.28%
2 Years
92.45%
0.10%
92.55%
3 Years
154.19%
0.13%
154.32%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Latest dividend: 0.5 per share ex-dividend date: Aug-14-2026

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions

News

Yatharth Hospital & Trauma Care Services Ltd Declines 2.90% Despite New Highs: 5 Key Factors Driving the Week

Key Events This Week

10 Aug: New 52-week and all-time high at Rs.899.35

11 Aug: Fresh 52-week and all-time high at Rs.920.20

12 Aug: Technical momentum shifts signal bullish outlook despite price dip

14 Aug: Week closes at Rs.845.00, down 2.90% for the week

Announcements stock-summary

Announcement under Regulation 30 (LODR)-Monitoring Agency Report

13-Aug-2026 | Source : BSE

We hereby submit Monitoring Agency Report for the quarter ended June 30 2026 (IPO).

Announcement under Regulation 30 (LODR)-Newspaper Publication

11-Aug-2026 | Source : BSE

We hereby submit Newspaper Publication of Unaudited Financial Results - Q1FY27.

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

11-Aug-2026 | Source : BSE

We hereby submit Earnings Call Recording for Q1FY27.

Corporate Actions stock-summary

stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

Yatharth Hospital & Trauma Care Services Ltd has declared 5% dividend, ex-date: 14 Aug 26

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
33.26%
EBIT Growth (5y)
19.96%
EBIT to Interest (avg)
20.46
Debt to EBITDA (avg)
0.35
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0.65
Tax Ratio
22.49%
Dividend Payout Ratio
0
Pledged Shares
9.59%
Institutional Holding
16.47%
ROCE (avg)
17.68%
ROE (avg)
9.01%

Valuation key factors

Factor
Value
P/E Ratio
46
Industry P/E
66
Price to Book Value
4.64
EV to EBIT
39.47
EV to EBITDA
26.61
EV to Capital Employed
4.64
EV to Sales
6.19
PEG Ratio
1.66
Dividend Yield
0.06%
ROCE (Latest)
10.97%
ROE (Latest)
9.89%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bearish
Dow Theory
Bullish
Bullish
OBV
Mildly Bullish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2026stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

9.5903

Mutual Funds

Held by 7 Schemes (9.74%)

FIIs

Held by 58 FIIs (5.62%)

Promoter with highest holding

Ajay Kumar Tyagi (30.59%)

Highest Public shareholder

Kotak Mahindra Trustee Co Ltd A/c Kotak Multicap Fund (5%)

Individual Investors Holdings

19.83%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2026 is 14.96% vs 6.58% in Mar 2026",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2026 is -0.97% vs 4.79% in Mar 2026",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'26",
        "Mar'26",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "392.65",
          "val2": "341.56",
          "chgp": "14.96%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "91.68",
          "val2": "79.91",
          "chgp": "14.73%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "6.59",
          "val2": "5.07",
          "chgp": "29.98%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "47.06",
          "val2": "47.52",
          "chgp": "-0.97%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "23.35%",
          "val2": "23.40%",
          "chgp": "-0.05%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Consolidated) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2025 is 25.06% vs 31.85% in Sep 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": " Growth in half year ended Sep 2025 is 35.77% vs 31.52% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "537.19",
          "val2": "429.55",
          "chgp": "25.06%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "129.01",
          "val2": "108.30",
          "chgp": "19.12%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.45",
          "val2": "4.48",
          "chgp": "-89.96%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "83.28",
          "val2": "61.34",
          "chgp": "35.77%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "24.02%",
          "val2": "25.21%",
          "chgp": "-1.19%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is 32.21% vs 31.70% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is 40.07% vs 20.62% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "857.66",
          "val2": "648.71",
          "chgp": "32.21%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "203.26",
          "val2": "163.22",
          "chgp": "24.53%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.47",
          "val2": "6.54",
          "chgp": "-77.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "128.63",
          "val2": "91.83",
          "chgp": "40.07%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "23.70%",
          "val2": "25.16%",
          "chgp": "-1.46%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2026 is 37.10% vs 31.31% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2026 is 34.34% vs 14.04% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,207.17",
          "val2": "880.49",
          "chgp": "37.10%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "292.12",
          "val2": "220.19",
          "chgp": "32.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "6.54",
          "val2": "7.51",
          "chgp": "-12.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "175.38",
          "val2": "130.55",
          "chgp": "34.34%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "24.20%",
          "val2": "25.01%",
          "chgp": "-0.81%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQstock-summary

Jun'26
Mar'26
Change(%)
Net Sales
392.65
341.56
14.96%
Operating Profit (PBDIT) excl Other Income
91.68
79.91
14.73%
Interest
6.59
5.07
29.98%
Exceptional Items
0.00
0.00
Consolidate Net Profit
47.06
47.52
-0.97%
Operating Profit Margin (Excl OI)
23.35%
23.40%
-0.05%
Values in Rs Cr.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2026 is 14.96% vs 6.58% in Mar 2026

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2026 is -0.97% vs 4.79% in Mar 2026

Half Yearly Results Snapshot (Consolidated) - Sep'25stock-summary

Sep'25
Sep'24
Change(%)
Net Sales
537.19
429.55
25.06%
Operating Profit (PBDIT) excl Other Income
129.01
108.30
19.12%
Interest
0.45
4.48
-89.96%
Exceptional Items
0.00
0.00
Consolidate Net Profit
83.28
61.34
35.77%
Operating Profit Margin (Excl OI)
24.02%
25.21%
-1.19%
Values in Rs Cr.
Direction Arrows
Net Sales

Growth in half year ended Sep 2025 is 25.06% vs 31.85% in Sep 2024

Direction Arrows
Consolidated Net Profit

Growth in half year ended Sep 2025 is 35.77% vs 31.52% in Sep 2024

Nine Monthly Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
857.66
648.71
32.21%
Operating Profit (PBDIT) excl Other Income
203.26
163.22
24.53%
Interest
1.47
6.54
-77.52%
Exceptional Items
0.00
0.00
Consolidate Net Profit
128.63
91.83
40.07%
Operating Profit Margin (Excl OI)
23.70%
25.16%
-1.46%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in nine months ended Dec 2025 is 32.21% vs 31.70% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in nine months ended Dec 2025 is 40.07% vs 20.62% in Dec 2024

Annual Results Snapshot (Consolidated) - Mar'26stock-summary

Mar'26
Mar'25
Change(%)
Net Sales
1,207.17
880.49
37.10%
Operating Profit (PBDIT) excl Other Income
292.12
220.19
32.67%
Interest
6.54
7.51
-12.92%
Exceptional Items
0.00
0.00
Consolidate Net Profit
175.38
130.55
34.34%
Operating Profit Margin (Excl OI)
24.20%
25.01%
-0.81%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2026 is 37.10% vs 31.31% in Mar 2025

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2026 is 34.34% vs 14.04% in Mar 2025

stock-summaryCompany CV
About Yatharth Hospital & Trauma Care Services Ltd stock-summary
stock-summary
Yatharth Hospital & Trauma Care Services Ltd
Small Cap
Hospital
Yatharth Hospital & Trauma Care Services Limited was formerly incorporated as a Private Limited Company in Delhi dated February 28, 2008. On November 3, 2021, the status converted into a Public Company and name of the Company was changed to `Yatharth Hospital & Trauma Care Services Limited' on November 18, 2021 issued by the RoC.
Company Coordinates stock-summary
Icon
No Company Details Available